Pyridam Farma Tbk PT
IDX:PYFA

Watchlist Manager
Pyridam Farma Tbk PT Logo
Pyridam Farma Tbk PT
IDX:PYFA
Watchlist
Price: 234 IDR Market Closed
Market Cap: 2.6T IDR

Relative Value

The Relative Value of one PYFA stock under the Base Case scenario is 355.51 IDR. Compared to the current market price of 234 IDR, Pyridam Farma Tbk PT is Undervalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PYFA Relative Value
Base Case
355.51 IDR
Undervaluation 34%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
46
vs Industry
62
Median 3Y
1.2
Median 5Y
1.3
Industry
2.5
vs History
vs Industry
43
Median 3Y
-6.8
Median 5Y
1.8
Industry
21.3
vs History
vs Industry
22
Median 3Y
-2.5
Median 5Y
11.6
Industry
16.7
vs History
61
vs Industry
36
Median 3Y
1.3
Median 5Y
1.7
Industry
24.7
vs History
58
vs Industry
46
Median 3Y
2.4
Median 5Y
3.1
Industry
2.1
vs History
25
vs Industry
31
Median 3Y
2.8
Median 5Y
1.8
Industry
2.6
vs History
17
vs Industry
15
Median 3Y
9.8
Median 5Y
4.3
Industry
5.1
vs History
vs Industry
0
Median 3Y
3.6
Median 5Y
11
Industry
12.8
vs History
vs Industry
0
Median 3Y
3.6
Median 5Y
11
Industry
16.3
vs History
vs Industry
8
Median 3Y
-10.5
Median 5Y
18.2
Industry
14.9
vs History
vs Industry
7
Median 3Y
-4.2
Median 5Y
-5.1
Industry
18.2
vs History
65
vs Industry
57
Median 3Y
1.1
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

PYFA Competitors Multiples
Pyridam Farma Tbk PT Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Pyridam Farma Tbk PT
IDX:PYFA
2.6T IDR 1.4 -8 -51.8 -51.8
US
Eli Lilly and Co
NYSE:LLY
725.7B USD 14.8 65.3 35.1 38.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
369.6B USD 4.1 16.9 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7 20.2 14 16
CH
Roche Holding AG
SIX:ROG
212.9B CHF 3.5 25.7 9.6 11.3
CH
Novartis AG
SIX:NOVN
188.6B CHF 4.3 18 10.6 14.2
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP 4.1 28.9 131.1 197.6
US
Merck & Co Inc
NYSE:MRK
195.3B USD 3.1 11.2 8.4 10.2
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
131.7B USD 2.1 16.7 7.2 10.2
P/E Multiple
Earnings Growth PEG
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average P/E: 25.4
Negative Multiple: -8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
65.3
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.9
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.7
32%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.2
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.7
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average EV/EBITDA: 433.6
Negative Multiple: -51.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.1
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
14
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.6
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.1
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.4
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average EV/EBIT: 1 867.2
Negative Multiple: -51.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.4
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
16
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.3
6%
1.9
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.6
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.2
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1